Dr Herbert H. Loong shares his views on the latest data on oncogene-addicted non-small cell lung cancer (NSCLC) presented at the WCLC and ESMO 2024 congresses.
Dr Loong reviews data and provides his key clinical takeaways from the studies below.
Clinical takeaways
ROS1
- TRUST-II: Taletrectinib demonstrated high and durable overall responses, robust IC activity in TKI-naïve and TKI-pretreated patients with ROS1+ NSCLC, and is a potential new therapy for this patient population. Data from TRUST-II supports the efficacy and safety of taletrectinib across regions and ethnicities [Liu G, et al. Abstract MA06.03, WCLC 2024]
KRAS
- LOXO-RAS-20001: demonstrates the feasibility of combining KRAS G12C inhibitors with chemotherapy and immunotherapy. Preliminary efficacy was demonstrated with an ORR of 50% in a higher risk (PD-L1 low/negative) population. Olomorasib combined with chemo-immunotherapy demonstrated a manageable safety profile [Fujiwara Y, et al. Abstract OA14.04, WCLC 2024]
HER2 mutations
- SOHO-01: Treatment with BAY 2927088 led to rapid, substantial, and durable responses in patients with heavily pretreated HER2-mutant NSCLC. The safety profile of BAY 2927088 was manageable and consistent with previous reports [Le X, et al. Abstract PL04.03, WCLC 2024]
- Beamion LUNG-1: Zongertinib demonstrated significant and clinically meaningful activity in patients with pre-treated NSCLC with a HER2 TKD mutation, including in those with brain metastases and was well tolerated [Ruiter G, et al. Abstract PL04.04, WCLC 2024]
HER2 Over expression
- DESTINY-Lung03: T-DXd monotherapy demonstrated encouraging antitumor activity in patients with pretreated advanced or metastatic HER2-OE NSCLC, and had an acceptable safety profile, consistent with the known profile of T-DXd [Planchard D, et al. Abstract OA16.05, WCLC 2024]
ALK
- ALKOVE-1: NVL-655 was well-tolerated and the emerging safety profile was consistent with ALK-selective, TRK-sparing design. Durable responses were observed in a heavily pre-treated population and across patient subgroups [Drilon A, et al. Abstract 1253O, ESMO 2024]
EGFR
- MARIPOSA: Amivantamab plus lazertinib had significantly reduced the incidence of MET amplifications and EGFR resistance alterations versus osimertinib [Besse B, et al. Abstract LBA55, ESMO 2024]
Watch the short video update and download the accompanying slides to see the key data from these trials.